Junichiro Watanabe

List of Publications by Year
in descending order

91	6,608	331259	114278
papers	citations	21 h-index	63 g-index

93	93	93	7659
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study. BMC Cancer, 2022, 22, 31.	1.1	2
2	Evaluation of Breast Edema Findings at T2-weighted Breast MRI Is Useful for Diagnosing Occult Inflammatory Breast Cancer and Can Predict Prognosis after Neoadjuvant Chemotherapy. Radiology, 2021, 299, 53-62.	3.6	24
3	Can breast MRI and adjunctive Doppler ultrasound improve the accuracy of predicting pathological complete response after neoadjuvant chemotherapy?. Breast Cancer, 2021, 28, 1120-1130.	1.3	6
4	Leptomeningeal Metastasis in ERâ€‰+â€‰HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period. Breast Cancer Research and Treatment, 2021, 189, 225-236.	1.1	12
5	Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. New England Journal of Medicine, 2021, 384, 2394-2405.	13.9	764
6	Exposureâ€Response Relationships in Patients With HER2â€Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan. Clinical Pharmacology and Therapeutics, 2021, 110, 986-996.	2.3	20
7	Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 5771-5780.	3.2	15
8	The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution. Anticancer Research, 2021, 41, 4619-4627.	0.5	2
9	Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study. Scientific Reports, 2021, 11, 21454.	1.6	1
10	Hepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic Chemotherapies. In Vivo, 2020, 34, 275-282.	0.6	5
11	Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy. In Vivo, 2020, 34, 1377-1386.	0.6	4
12	147P Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours. Annals of Oncology, 2020, 31, S68-S69.	0.6	0
13	Reply to letters to the editor: Discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer. Breast Cancer Research and Treatment, 2020, 182, 513-514.	1.1	2
14	High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulinâ€”but not with treatment of physicianâ€™s choiceâ€”in the EMBRACE study. Breast Cancer, 2020, 27, 706-715.	1.3	41
15	Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2020, 382, 810-821.	13.9	1,542
16	Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?. European Radiology, 2020, 30, 3363-3370.	2.3	20
17	A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. Breast Cancer Research and Treatment, 2020, 181, 211-220.	1.1	24
18	Abstract P1-18-12: A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer. , 2020, , .		6

#	Article	IF	Citations
19	Abstract P1-10-25: The prognostic and predictive roles of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio in HER2-negative metastatic breast cancer patients treated with paclitaxel-bevacizumab. , 2020, , .		0
20	Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumours. Annals of Oncology, 2019, 30, v116-v117.	0.6	4
21	Imaging features of breast cancer with marked hemosiderin deposition: A case report. European Journal of Radiology Open, 2019, 6, 302-306.	0.7	1
22	MRI-detected breast lesions: clinical implications and evaluation based on MRI/ultrasonography fusion technology. Japanese Journal of Radiology, 2019, 37, 685-693.	1.0	12
23	A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. British Journal of Cancer, 2019, 120, 475-480.	2.9	92
24	Phase I study of BI 836880, a VEGF/Ang2-blocking nanobodyÂ®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours. Annals of Oncology, 2019, 30, ix28-ix29.	0.6	4
25	ADVANCED INVASIVE LOBULAR CARCINOMA, REAL WORLD EXPERIENCES IN SINGLE INSTITUTION. Breast, 2019, 48, S57.	0.9	1
26	Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis. Breast Cancer Research and Treatment, 2018, 167, 81-87.	1.1	15
27	Clinical utility of hepatic arterial infusion chemotherapy for heavily pretreated metastatic breast cancer patients: A review of a single institution. Annals of Oncology, 2018, 29, viii101-viii102.	0.6	0
28	Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2â€“) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET). Annals of Oncology, 2018, 29, ix13-ix14.	0.6	0
29	Ribociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2â€“) advanced breast cancer (ABC). Annals of Oncology, 2018, 29, ix14-ix15.	0.6	0
30	Re-challenging eribulin in patients with ER+HER2- metastatic breast cancer: A single-institution experience. Annals of Oncology, 2018, 29, ix20.	0.6	0
31	Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. British Journal of Cancer, 2018, 118, 1571-1579.	2.9	2
32	Abstract P1-17-09: Leptomeningeal disease in ER+HER2- metastatic breast cancer patients: A review of the cases in a single institute over a 14-year period. , 2018, , .		0
33	Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. Breast Cancer Research and Treatment, 2017, 162, 169-179.	1.1	29
34	Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 162, 501-510.	1.1	13
35	Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. Breast Cancer Research and Treatment, 2017, 161, 473-482.	1.1	7
36	Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. Breast Cancer Research and Treatment, 2017, 166, 911-917.	1.1	14

#	Article	IF	Citations
37	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1688-1700.	5.1	451
38	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine, 2017, 377, 122-131.	13.9	1,033
39	Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. Investigational New Drugs, 2017, 35, 791-799.	1.2	16
40	Does the Choice of First-Line Chemotherapy Influence the Outcome of ER+HER2: Metastatic Breast Cancer?. Breast, 2017, 36, S61.	0.9	0
41	A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Annals of Oncology, 2017, 28, v80-v81.	0.6	3
42	Eribulin mesylate for HER2- metastatic breast cancer; analyses of pattern of disease progression and outcomes from the real world. Annals of Oncology, 2017, 28, x31.	0.6	0
43	Durable complete response in HER2-positive breast cancer: A multicenter retrospective analysis. Annals of Oncology, 2017, 28, v101.	0.6	0
44	Randomized phase II study of nabâ€paclitaxel as firstâ€line chemotherapy in patients with HER2â€negative metastatic breast cancer. Cancer Science, 2017, 108, 987-994.	1.7	18
45	The utility of risk factors proposed in a prospective clinical trial in the management of ER-positive, HER2-negative metastatic breast cancer patients: Feedback from the real world. Annals of Oncology, 2017, 28, x31.	0.6	0
46	A call for global harmonization of phase I oncology trials: Results from two parallel, first-in-human phase I studies of DS-7423, an oral PI3K/mTOR dual inhibitor in advanced solid tumors conducted in the United States and Japan.. Journal of Clinical Oncology, 2017, 35, 2536-2536.	0.8	3
47	Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. In Vivo, 2017, 31, 493-500.	0.6	13
48	Abstract OT1-01-01: A phase II, open-label, multicenter, translational study for biomarkers of eribulin mesylate: Evaluation of the utility of monitoring epithelial-to-mesenchymal transition (EMT) markers on tumor cells in the malignant plural effusion of patients with metastatic breast cancer (EXPECT-study). Cancer Research, 2017, 77, OT1-01-01-OT1-01-01.	0.4	1
49	Early-onset neutropenia-related events in eribulin monotherapy: A possible biomarker in the real world?. Journal of Clinical Oncology, 2017, 35, e12529-e12529.	0.8	0
50	Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases. BMC Cancer, 2016, 16, 391.	1.1	15
51	Is the overall survival after hormone therapy for hormone-receptor-positive, HER2-negative metastatic breast cancer still better than for triple-negative metastatic breast cancer?. Annals of Oncology, 2016, 27, vi82.	0.6	1
52	Real-time virtual sonography examination and biopsy for suspicious breast lesions identified on MRI alone. European Radiology, 2016, 26, 1064-1072.	2.3	26
53	PO60 THE ROLE OF LAPATINIB IN THE MANAGEMENT OF HER2-POSITIVE METASTATIC BREAST CANCER: A REVIEW OF A SINGLE INSTITUTION'S EXPERIENCE DURING THE TRASTUZUMAB AND LAPATINIB ERA. Breast, 2015, 24, S42.	0.9	0
54	1858 The improvement of overall survivals in patients with metastatic breast cancer by zoledronic acid: The assessment of the real world. European Journal of Cancer, 2015, 51, S284-S285.	1.3	0

#	Article	IF	Citations
55	Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review. SpringerPlus, 2015, 4, 625.	1.2	24
56	Profiting from IoT: the key is very-large-scale happiness integration. , 2015, , .		7
57	Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2015, 372, 724-734.	13.9	1,658
58	Metastatic breast carcinoma of the abdominal wall muscle: a case report. Breast Cancer, 2015, 22, 206-209.	1.3	14
59	Abstract P6-16-06: Impact of early detection of brain metastasis in metastatic breast cancer patients: A single institutional experience. , 2015, , .		0
60	Phase I Clinical Trial of Ds-7423, an Oral Pi3K/Mtor Dual Inhibitor, in Japanese Patients with Advanced Solid Tumors. Annals of Oncology, 2014, 25, iv153.	0.6	2
61	Eribulin in Her2 Negative Metastatic Breast Cancer, Assessment of Overall Survival in Real World. Annals of Oncology, 2014, 25, iv130.	0.6	0
62	Is evaluation of the presence of prepectoral edema on T2-weighted with fat-suppression 3ÂT breast MRI a simple and readily available noninvasive technique for estimation of prognosis in patients with breast cancer?. Breast Cancer, 2014, 21, 684-692.	1.3	51
63	Can T2-weighted 3-T breast MRI predict clinically occult inflammatory breast cancer before pathological examination? A single-center experience. Breast Cancer, 2014, 21, 115-121.	1.3	17
64	An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3Âweeks in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 73, 623-630.	1.1	8
65	Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 74, 629-636.	1.1	32
66	Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan. Cancer Chemotherapy and Pharmacology, 2013, 71, 1427-1433.	1.1	10
67	First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours. Investigational New Drugs, 2013, 31, 108-114.	1.2	21
68	PO69 ERIBULIN IN PRACTICE, REVIEW OF 70 CASES FROM SINGLE INSTITUTE AND COMPARISON WITH JAPAN PHASE 2 STUDY. Breast, 2013, 22, S43-S44.	0.9	0
69	PO100 LONG-TERM BONE MANAGEMENT BY BISPHOSPHONATE IN METASTATIC BREAST CANCER PATIENTS. Breast, 2013, 22, S53.	0.9	1
70	Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2012, 30, 2352-2363.	1.2	62
71	Should breast MRI be performed with adjustment for the phase in patientsâ€™ menstrual cycle? Correlation between mammographic density, age, and background enhancement on breast MRI without adjusting for the phase in patientsâ€™ menstrual cycle. European Journal of Radiology, 2012, 81, 1539-1542.	1.2	30
72	Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 70, 407-414.	1.1	24

#	Article	IF	Citations
73	Phase I Study of Ombrabulin, a Vascular Disrupting Agent (VDA), Administered Every 3 Weeks to Japanese Patients with Advanced Solid Tumors. Annals of Oncology, 2012, 23, xi110.	0.6	0
74	Background enhancement of mammary glandular tissue on breast dynamic MRI: imaging features and effect on assessment of breast cancer extent. Breast Cancer, 2012, 19, 259-265.	1.3	24
75	Clip placement after an 11-gauge vacuum-assisted stereotactic breast biopsy: correlation between breast thickness and clip movement. Breast Cancer, 2012, 19, 30-36.	1.3	15
76	Abstract P1-12-01: Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase III study (JO21095). , 2012, , .		1
77	Abstract P5-18-16: A Multicenter Phase 2 Study (JO22997) Evaluating the Efficacy and Safety of Trastuzumab Emtansine in Japanese Patients With Heavily Pretreated HER2-Positive Metastatic Breast Cancer. , 2012, , .		2
78	Abstract P6-07-16: Evaluation of circulating tumor cell as a marker of prognosis and efficacy in a randomized phase III study in HER2 negative metastatic breast cancer patients treated with capecitabine and docetaxel: JO21095 study. , 2012, , .		0
79	5065 POSTER Trastuzumab Responder Will Show Good Repose to Lapatinib. European Journal of Cancer, 2011, 47, S349-S350.	1.3	0
80	5067 POSTER A Phase 1 Study of Neratinib in Combination With Vinorelbine in Japanese Patients With Advanced or Metastatic Solid Tumours. European Journal of Cancer, 2011, 47, S350.	1.3	1
81	1252 POSTER First Report of the Safety, Tolerability, and Pharmacokinetics of Saracatinib (AZD0530) in Japanese Patients With Advanced Solid Tumours. European Journal of Cancer, 2011, 47, S160.	1.3	0
82	Chronology of HER2 disease. Breast, 2011, 20, S39-S40.	0.9	0
83	Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer?. European Radiology, 2011, 21, 2261-2267.	2.3	85
84	Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?. Breast Cancer, 2011, 18, 309-313.	1.3	34
85	Breast cancer leptomeningeal metastasis.. Journal of Clinical Oncology, 2011, 29, e11524-e11524.	0.8	0
86	Lapatinib plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.. Journal of Clinical Oncology, 2011, 29, e11003-e11003.	0.8	0
87	P4-17-11: Central Nervous System Involvement and Clinical Outcome, Review of 135 Patients, 9-Year Follow Up.. , 2011, , .		0
88	Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. British Journal of Cancer, 2009, 101, 1676-1682.	2.9	87
89	Comparison of FDG PET and SPECT for Detection of Bone Metastases in Breast Cancer. American Journal of Roentgenology, 2005, 184, 1266-1273.	1.0	124
90	Autologous Stem Cell Transplantations for Recurrent Adult T Cell Leukaemia/Lymphoma Using Highly Purified CD34+ Cells Derived from Cryopreserved Peripheral Blood Stem Cells. Leukemia and Lymphoma, 2001, 42, 1115-1117.	0.6	8

#	Article	IF	Citations
91	An Unusual Association of Monoclonal Gammopathy, Paroxysmal Nocturnal Haemoglobinuria and Myelodysplastic Syndrome Transformed into Acute Myeloid Leukaemia: Coexistence of Triple Clonal Disorders. Leukemia and Lymphoma, 2001, 42, 813-817.	0.6	1